Zogenix Risks Fintepla Uptake With Dravet Drug’s High Price

Zogenix Inc. won US Food and Drug Administration approval for Fintepla (fenfluramine) in the treatment of Dravet syndrome, a rare form of epilepsy that patients begin to experience in infancy, but set a list price that is three times the cost of another relatively new drug for the disease, raising questions about whether the price will limit uptake.

The US FDA approved Fintepla on 25 June for the treatment of seizures associated with Dravet syndrome in patients age 2 and older – a broader population than the 2- to 18-year-old patients enrolled in Zogenix’s clinical trials